

patent term under 35 U.S.C. 156(d)(5) is appropriate.

A third interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,591,585 is granted for a period of one year from the expiration date of the patent, *i.e.*, until June 18, 2007.

Dated: June 12, 2006.

Jon W. Dudas

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

[FR Doc. E6-9489 Filed 6-15-06; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-P-2006-0033]

Grant of Interim Extension of the Term of U.S. Patent No. 4,585,597; ANTHÉLIOS SP (HELIOBLOCK SX Cream) (Mexoryl SX (Ecamsule))

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a fourth one-year interim extension of the term of U.S. Patent No. 4,585,597.

FOR FURTHER INFORMATION CONTACT:

Mary C. Till by telephone at (571) 272-7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-7755, or by e-mail to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On May 16, 2006, patent owner, L'Oreal S.A., timely filed an application under 35 U.S.C. 156(d)(5) for a fourth subsequent interim extension of the term of U.S. Patent No. 4,585,597. The patent claims the active ingredient Mexoryl SX (ecamsule), in the human drug product ANTHELIOS SP (HELIOBLOCK SX Cream), a method of

use of the active ingredient, and a method of manufacturing the active ingredient. The application indicates, and the Food and Drug Administration has confirmed, that a New Drug Application for the human drug product Mexoryl SX (ecamsule) has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially.

Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for an additional year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (June 16, 2006), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. A fourth interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,585,597 is granted for a period of one year from the extended expiration date of the patent, *i.e.*, until June 16, 2007.

Dated: June 12, 2006.

Jon W. Dudas,

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

[FR Doc. E6-9490 Filed 6-15-06; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-P-2006-0019]

Grant of Interim Extension of the Term of U.S. Patent No. 4,850,962; Esteem (Totally Implantable Hearing System)

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,850,962.

FOR FURTHER INFORMATION CONTACT:

Mary C. Till by telephone at (571) 272-7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-7755, or by e-mail to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On March 31, 2006, patent owner, Envoy Medical Corporation, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 4,850,962. The patent claims the medical device Esteem (totally implantable hearing system). The application indicates that an Investigational Device Exemption for the medical device Esteem has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially.

Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the original expiration date of the patent (July 25, 2006), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 4,850,962 is granted for a period of one year from the original expiration date of the patent, *i.e.*, until July 25, 2007.

Dated: June 12, 2006.

Jon W. Dudas,

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office.

[FR Doc. E6-9494 Filed 6-15-06; 8:45 am]

BILLING CODE 3510-16-P

COMMODITY FUTURES TRADING COMMISSION

Sunshine Act Meeting

TIME AND DATE: 11 a.m., Friday, July 7, 2006.

PLACE: 1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.

STATUS: Closed.

MATTERS TO BE CONSIDERED: Surveillance Matters.

FOR FURTHER INFORMATION CONTACT:

Eileen A. Donovan, 202-418-5100.

Eileen A. Donovan,

Acting Secretary of the Commission.

[FR Doc. 06-5518 Filed 6-14-06; 1:32 pm]

BILLING CODE 6351-01-M

COMMODITY FUTURES TRADING COMMISSION**Sunshine Act Meeting****TIME AND DATE:** 11 a.m., Friday, July 28, 2006.**PLACE:** 1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.**STATUS:** Closed.**MATTERS TO BE CONSIDERED:** Surveillance Matters.**FOR FURTHER INFORMATION CONTACT:**

Eileen A. Donovan, 202-418-5100.

Eileen A. Donovan,

Acting Secretary of the Commission.

[FR Doc. 06-5519 Filed 6-14-06; 1:32 pm]

BILLING CODE 6351-01-M

COMMODITY FUTURES TRADING COMMISSION**Sunshine Act Meeting****TIME AND DATE:** 11 a.m., Friday, July 21, 2006.**PLACE:** 1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.**STATUS:** Closed.**MATTERS TO BE CONSIDERED:** Enforcement Matters.**FOR FURTHER INFORMATION CONTACT:**

Eileen A. Donovan, 202-418-5100.

Eileen A. Donovan,

Acting Secretary of the Commission.

[FR Doc. 06-5520 Filed 6-14-06; 8:45 am]

BILLING CODE 6351-01-M

COMMODITY FUTURES TRADING COMMISSION**Sunshine Act Meeting****TIME AND DATE:** 11 a.m., Friday, July 14, 2006.**PLACE:** 1155 21st St., NW., Washington, DC., 9th Floor Commission Conference Room.**STATUS:** Closed.**MATTERS TO BE CONSIDERED:** Surveillance Matters.**FOR FURTHER INFORMATION CONTACT:**

Eileen A. Donovan, 202-418-5100.

Eileen A. Donovan,

Acting Secretary of the Commission.

[FR Doc. 06-5521 Filed 6-14-06; 1:32 pm]

BILLING CODE 6351-01-M

DEPARTMENT OF DEFENSE**[DOD-2006-OS-0121]****Defense Finance and Accounting Service; Privacy Act of 1974; Systems of Records****AGENCY:** Defense Finance and Accounting Service.**ACTION:** Notice to add a new system of records.**SUMMARY:** The Defense Finance and Accounting Service (DFAS) is proposing to add a system of records notice to its inventory of record systems subject to the Privacy Act of 1974, (5 U.S.C. 552a), as amended.**DATES:** This Action will be effective without further notice on July 17, 2006 unless comments are received that would result in a contrary determination.**ADDRESSES:** Send comments to the FOIA/PA Program Manager, Corporate Communications and Legislative Liaison, Defense Finance and Accounting Service, 6760 E. Irvington Place, Denver, CO 90279-8000.**FOR FURTHER INFORMATION CONTACT:** Ms. Linda Krabbenhoft at (303) 676-6045.**SUPPLEMENTARY INFORMATION:** The Defense Finance and Accounting Service notices for systems of records subject to the Privacy Act of 1974 (5 U.S.C. 552a), as amended, have been published in the **Federal Register** and are available from the address above.

The proposed system report, as required by 5 U.S.C. 552a(r) of the Privacy Act of 1974, as amended, was submitted on June 6, 2006, to the House Committee on Government Reform, the Senate Committee on Governmental Affairs, and the Office of Management and Budget (OMB) pursuant to paragraph 4c of Appendix I to OMB Circular No. A-130, "Federal Agency Responsibilities for Maintaining Records About Individuals," dated December 12, 2000, 65 FR 239.

Dated: June 12, 2006.

C.R. Choate,*Alternate OSD Federal Register Liaison Officer, Department of Defense.***T7336****SYSTEM NAME:**

MyPay System.

SYSTEM LOCATION:

Defense Finance and Accounting Service—Cleveland, 1240 East Ninth Street, Cleveland, OH 44199.

Office of Personnel Management, 4685 Log Cabin Drive, Macon, GA 31204-6317.

CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:

Active Duty and Reserve military personnel, members of the National Guard, military academy cadets, Naval Reserve Officer Training Corps students, and Armed Forces Health Professions Scholarship Program (AFHPSP) students.

All DoD civilian employees paid by appropriated funds.

All Army nonappropriated fund instrumentalities employees paid by nonappropriated funds.

Military retirees, their former spouses (Former Spouse Protection Act (FSPA) Claimants), and annuitants.

Executive Office of the President employees.

Department of Health and Human Services employees.

Department of Energy employees.

CATEGORIES OF RECORDS IN THE SYSTEM:

Individual's Name, Social Security Number, employing DoD and other Federal agencies, military branch of service, status (as appropriate), and e-mail addresses are maintained in the Master PIN Database (MPDB).

AUTHORITY FOR MAINTENANCE OF THE SYSTEM:

5 U.S.C. 301, Departmental Regulations; 5 U.S.C. Chapter 53, 55, and 81; and E.O. 9397 (SSN).

PURPOSE(S):

The MyPay System is a combination Internet (WEB) based and interactive voice response telephonic system (IVRS) designed to allow authorized individuals the ability to retrieve, review and update payroll information from their specific payroll system(s). Records are also used for extraction or compilation of data and reports for management studies and statistical analyses for use internally or externally as required by DoD or other government agencies.

ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES:

In addition to those disclosures generally permitted under 5 U.S.C. 552a(b) of the Privacy Act, these records or information contained therein may specifically be disclosed outside the DoD as a routine use pursuant to 5 U.S.C. 552a(b)(3) as follows:

To Federal, State, and local agencies for the purpose of conducting computer